Evaxion Biotech A/S

11:15 AM - 11:30 AM (PDT), Tuesday, June 14, 2022
We are an AI-immunologyTM platform company decoding the human immune system to discover and develop novel immunotherapies for cancer and infectious diseases.

We have developed our AI-immunology core technology to deeply understand the biological processes relevant for engaging the immune system so we can harness its powers through novel immunotherapies. Our scalable AI-immunology core technology enables broad applicability across diseases with immunological components. With deep insights into the biological processes of the immune system, we bridge technology, engineering expertise and drug development know-how to bring novel immunotherapies to patients.
Ticker:
EVAX
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company HQ State:
Not Provided
Company HQ Country:
Denmark
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
EVX-01
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4+